Dear Lam Research Investors, Mark Your Calendars for April 22: Its Stock May Not Look Back

Lam guides Q3 FY26 revenue to $5.70B ahead of an April 22 print after Q2 revenue of $5.344B (+22.1% YoY) and non-GAAP EPS of $1.27 (beat ~8.7%). Management expects gross margin near ~49% (down from 50.6% in Q1 and 49.6% in Q2) and flags tariff/China risks (China = 35% of Q2 revenue vs 43% in Q1); systems revenue trajectory and Q4 guidance tone are key catalysts. Shares have pulled back from $252.41 to ~$218.90 despite being +27.8% YTD and could re-rate toward the $274.90 analyst target if Lam delivers margin upside and confident guidance.

Analysis

Lam sits at an inflection where product-cycle durability (GAA, advanced packaging) matters more than any single quarter. If management can show sustained throughput gains from its molybdenum/deposition wins, that should translate into higher utilization at leading foundries and extend multi-year demand visibility — this is a structural revenue lever that compounds over 2-4 quarters as node transitions complete.

The near-term sensitivities are asymmetric: guidance tone and margin commentary will move the stock materially over days, but the deeper directional risk is geopolitical — incremental export controls or Chinese customer behavioral changes would show up as elongated lead times and potentially a re-routing of capex to non-U.S. tool vendors over 6-24 months. Tariff-driven margin pressure is a steady bleed on FCF unless mix shifts toward higher-margin service and installed-base revenue, which management can accelerate with aftermarket contracts.

Second-order winners include advanced-packaging subcontractors (Amkor-style players) and specialty consumables/sputter-target suppliers who will see lead-time and pricing power if deposition tools ramp. Conversely, increased China localization (if export frictions harden) would be a structural headwind to U.S.-centric tool makers and could compress multiples across the semicap cohort over multiple reporting cycles. The immediate trade is therefore to separate a beat-or-miss quarter (days) from the multi-quarter adoption story (quarters to years) and size positions accordingly.

Key Decisions for Investors

• Long LRCX equity (6–12 month horizon) — allocate 1–2% NAV: asymmetric upside if management confirms sustainable throughput gains; set a tactical stop at -18% and a take-profit band at +40–60% if guidance re-accelerates.
• Pair trade: Long LRCX / Short AMAT (1:1 notional, 3–6 month horizon) — isolates Lam's exposure to deposition/advanced-packaging wins versus Applied's broader memory/processing mix; target 15–25% relative return, cut if pair moves >12% against within 2 weeks.
• Buy AMKR (Amkor) 3–9 month (accumulate on pullbacks) — tactical lever to advanced-packaging adoption from Lam's wins; expect 20–30% upside if packaging ramps, downside capped by broader cyclical weakness (use 12% stop-loss).
• Options hedge or income: If neutral-to-bullish ahead of earnings, sell 30-day 7.5% OTM puts on LRCX sized to acquire stock at a favorable basis (max allocation 1% NAV) — collects premium and sets up a lower-cost entry; if outright long, buy 3-month 10% OTM puts to cap drawdown (cost <3% of notional) as earnings-event insurance.